Abstract
Positron Emission Tomography (PET) is increasingly being used in radiotherapy planning, with the development of hybrid imaging technology such as PET/CT allowing more accurate volumes being generated for treatment with external beam radiation. This article will discuss the use of FDG PET in radiotherapy planning of various types of malignancies, as well as some pitfalls and practicalities of integrating PET/CT into radiotherapy planning.
Keywords: PET/CT, radiotherapy planning, FDG, IMRT, head & neck carcinoma, lung carcinoma, gastrointestinal carcinoma, gynaecological carcinoma.
Current Radiopharmaceuticals
Title:The Current Role of PET/CT in Radiotherapy Planning
Volume: 8 Issue: 1
Author(s): Sze Ting Lee and Andrew M. Scott
Affiliation:
Keywords: PET/CT, radiotherapy planning, FDG, IMRT, head & neck carcinoma, lung carcinoma, gastrointestinal carcinoma, gynaecological carcinoma.
Abstract: Positron Emission Tomography (PET) is increasingly being used in radiotherapy planning, with the development of hybrid imaging technology such as PET/CT allowing more accurate volumes being generated for treatment with external beam radiation. This article will discuss the use of FDG PET in radiotherapy planning of various types of malignancies, as well as some pitfalls and practicalities of integrating PET/CT into radiotherapy planning.
Export Options
About this article
Cite this article as:
Lee Ting Sze and Scott M. Andrew, The Current Role of PET/CT in Radiotherapy Planning, Current Radiopharmaceuticals 2015; 8 (1) . https://dx.doi.org/10.2174/1874471008666150316222618
DOI https://dx.doi.org/10.2174/1874471008666150316222618 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiation Therapy in the Early 21st Century: Technological Advances
Current Cancer Therapy Reviews Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry Subject Index to Volume 4
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Small Bowel: An Imaging Guide
Current Medical Imaging [177Lu]-DOTA0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma
Current Radiopharmaceuticals Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy About a Long Lasting Primary Pleomorphic Adenoma of the Lung with a Misleading Pattern
Current Respiratory Medicine Reviews Preparation of Therapeutic Dose of <sup>177</sup>Lu-DOTA-TATE Using a Novel Single Vial Freeze-dried Kit: A Comparison with ‘In-situ’ Preparation at Hospital Radiopharmacy
Current Radiopharmaceuticals The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine The Production and Role of Gastrin-17 and Gastrin-17-Gly in Gastrointestinal Cancers
Protein & Peptide Letters PET Designated Flouride-18 Production and Chemistry
Current Topics in Medicinal Chemistry Pernicious Anemia: Fundamental and Practical Aspects in Diagnosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy
Current Medicinal Chemistry The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Toxicity and Tolerability of <sup>177</sup>Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin – A Phase 2 Registry Study
Current Radiopharmaceuticals Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Chromogranin A as a Calcium-Binding Precursor for a Multitude of Regulatory Peptides for the Immune, Endocrine and Metabolic Systems
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy
Current Pharmaceutical Design The Role of Neuroendocrine Cells in Prostate Cancer: A Comprehensive Review of Current Literature and Subsequent Rationale to Broaden and Integrate Current Treatment Modalities
Current Medicinal Chemistry